Moderna, Inc. reports developments in mRNA medicines, including commercial vaccines, investigational respiratory vaccines, oncology programs and rare-disease candidates. News commonly covers regulatory authorizations and agency interactions for products such as Spikevax, mRESVIA, mNEXSPIKE and mCOMBRIAX, as well as clinical data for seasonal influenza, pandemic influenza and cancer immunotherapy programs including intismeran autogene and mRNA-4359.
Company updates also include quarterly financial results, revenue mix, expense actions, strategic partnerships, scientific meeting presentations and intellectual-property matters tied to Moderna's infectious disease portfolio and broader mRNA technology platform.
Moderna (NASDAQ:MRNA) was named a top biopharmaceutical employer in Science and Science Careers’ survey for the twelfth consecutive year. The 2026 survey drew approximately 5,100 responses and recognized Moderna for its corporate image, leadership and direction, and work culture.
The company also highlighted its fourth and fifth product approvals: mCOMBRIAX, a combined influenza and COVID-19 vaccine, received European Union marketing authorization in April 2026; mFLUSIVA, a seasonal influenza vaccine, received FDA approval in August 2026. That August, Moderna and Merck announced positive topline results from the Phase 3 INTerpath-001 trial of investigational intismeran autogene with KEYTRUDA in patients with resected stage IIB-IV melanoma.
Merck (MRK) and Moderna (MRNA) reported Phase 3 results showing intismeran plus KEYTRUDA reduced melanoma recurrence or death risk by 42%. INTerpath-001 enrolled 1,137 patients with completely resected stage IIB-IV melanoma. At median follow-up of 24.6 months, the combination also reduced distant metastasis or death risk by 38% versus KEYTRUDA alone. Two-year recurrence-free survival was 82.2% versus 70.0%; survival without distant metastasis was 88.5% versus 80.2%.
Efficacy was comparable during the first six months. After six months, a pre-specified sensitivity analysis showed 58% lower recurrence or death risk. Overall survival data remain immature, with a favorable trend observed. Grade 3–5 treatment-related adverse events occurred in 14.2% versus 13.4%; no new safety signals emerged. The companies are engaging regulators. Results will be presented at ESMO 2026 and have been accepted for publication in The New England Journal of Medicine.
Moderna (MRNA) will report its third quarter 2026 financial results and provide a corporate update on November 6, 2026.
The live conference call and webcast will begin at 8:00 a.m. ET. The webcast will be accessible through the Investors section of Moderna's website, with an archive available approximately two hours after the call and for one year afterward.
Nasdaq (NDAQ) announced that Moderna will join the Nasdaq-100 Index before market open on October 9, 2026.
Moderna (MRNA) will replace Warner Bros. Discovery (WBD) as an index component. The Nasdaq-100 measures the performance of 100 of the largest Nasdaq-listed non-financial companies.
Moderna (MRNA) has appointed Juan Andres to its newly added Chief Operating Officer role, effective October 5, 2026. He will lead manufacturing, report to CEO Stéphane Bancel and join the Executive Committee. Chief Technical Operations and Quality Officer Jerh Collins has decided to retire.
Moderna is preparing for the potential launch and scale-up of intismeran autogene, jointly developed with Merck, following positive Phase 3 results. Its infectious disease franchise now includes five approved vaccines, following recent U.S. FDA approval of its seasonal flu vaccine and European Commission marketing authorization of its seasonal flu plus COVID combination vaccine.
Moderna (MRNA) will present late-breaking and additional clinical data on intismeran autogene, its investigational mRNA-based individualized neoantigen therapy, at the ESMO Congress 2026 in Madrid from October 23-27.
The company’s Phase 3 melanoma study INTerpath-001 (intismeran plus pembrolizumab vs pembrolizumab alone) is scheduled in the Presidential Symposium on Saturday, October 24, at 4:30 PM CEST / 10:30 AM EDT. Two poster sessions will cover a Phase I study in resectable pancreatic ductal adenocarcinoma (Sunday, October 25, 12:00-12:45 PM CET) and the Phase 3 INTerpath-014 trial in high-risk stage I NSCLC (Monday, October 26, 12:00-12:45 PM CET). Intismeran autogene is jointly developed by Moderna and Merck (MSD outside the US and Canada).
Moderna will also host a live investor webcast on Saturday, October 24, at 7:00 PM CEST / 1:00 PM EDT, with a replay available for at least 30 days.
Moderna (Nasdaq:MRNA) will participate in two investor events in September 2026: the Morgan Stanley 24th Annual Global Healthcare Conference on September 14 at 10:00 a.m. ET, and the Bernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum on September 23 at 8:50 a.m. ET.
Live webcasts and 30-day replays of both presentations will be accessible under “Events and Presentations” in the Investors section of Moderna’s website.
Moderna (NASDAQ:MRNA) priced an upsized private offering of $2.6 billion aggregate principal amount of 0.00% Convertible Senior Notes due 2032, sold to qualified institutional buyers under Rule 144A. The deal was increased from a previously announced $2.0 billion, with initial purchasers granted a $400 million option for additional notes.
The notes are senior unsecured, carry no regular interest, and mature on March 1, 2032, unless earlier converted, redeemed or repurchased. Moderna estimates net proceeds of about $2,562.9 million (or $2,957.3 million if the option is fully exercised), and expects to use approximately $285.0 million for capped call transactions and the remainder for general corporate purposes, potentially including oncology growth investments and debt repayment.
The initial conversion rate is 4.7487 shares per $1,000 (conversion price ~$210.58), a 47.5% premium to the $142.77 share price on August 27, 2026. Capped calls with a cap price of $392.6175 (a 175.0% premium) are intended to reduce dilution and/or offset cash payments above principal upon conversion, subject to customary adjustments and conditions.
Moderna (NASDAQ:MRNA) announced U.S. FDA approval of supplemental Biologics License Applications for its 2026-2027 formulas of Spikevax and mNEXSPIKE COVID-19 vaccines, updated to a monovalent JN.1-lineage XFG subvariant composition. According to Moderna, the updated Spikevax is approved for adults 65+ and for individuals 6 months through 64 years at high risk for severe COVID-19. mNEXSPIKE is approved for adults 65+ and for those 12 through 64 years at high risk.
Moderna said the updated vaccines are expected to be available in the U.S. in the coming days and that Spikevax’s 2026-2027 formula has already received approvals in Europe, South Korea, Singapore, Switzerland, the UK and other countries, while mNEXSPIKE has been approved in Japan, with additional regulatory reviews ongoing globally.
Moderna (NASDAQ:MRNA) plans a private placement of $2.0 billion aggregate principal amount of Convertible Senior Notes due 2032, offered only to qualified institutional buyers under Rule 144A. Initial purchasers are expected to receive an option to buy up to an additional $300 million of notes for 13 days after initial issuance.
The notes are senior unsecured obligations, bear no regular interest and have non‑accreting principal. Upon conversion, Moderna may settle in cash, stock or both. According to Moderna, net proceeds will fund capped call transactions and general corporate purposes, potentially including oncology growth investments and debt repayment. Moderna also expects to enter capped call hedges designed to reduce dilution up to a cap initially at least 150% of the stock price at pricing.